Media headlines about ContraVir Pharmaceuticals (NASDAQ:CTRV) have been trending somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ContraVir Pharmaceuticals earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.7638980871065 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of CTRV opened at $0.25 on Friday. ContraVir Pharmaceuticals has a 52 week low of $0.20 and a 52 week high of $1.85.
A number of analysts have commented on the company. ValuEngine raised ContraVir Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Maxim Group lowered ContraVir Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, February 13th.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/contravir-pharmaceuticals-ctrv-earns-daily-news-sentiment-rating-of-0-06.html.
ContraVir Pharmaceuticals Company Profile
ContraVir Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. The company engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection.
Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.